New pill shows promise in Hard-to-Treat eye cancer
NCT ID NCT06717126
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new drug called roginolisib against standard treatments in 85 adults with advanced uveal melanoma, a rare eye cancer. The study aims to see if roginolisib helps people live longer and improves their quality of life. Participants are randomly assigned to receive either roginolisib or the doctor's choice of standard therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- roginolisib (a drug taken by mouth)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced uveal melanoma that has stopped responding to immunotherapy.
- What could go wrong
- This is a mid-stage trial with only 85 participants, so results may not apply to everyone. The drug may not extend survival more than current treatments, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U.S. Santa Maria delle Scotte
Siena, 53100, Italy
-
Beatson West of Scotland Cancer Centre, Glasgow (NHS Greater Glasgow & Clyde)
Glasgow, G12 0YN, United Kingdom
-
Complejo Hospitalario Universitario de Santiago - CHUS
Santiago de Compostela, 15706, Spain
-
Consorcio Hospital General Universitario de València - CHGUV
Valencia, 46014, Spain
-
East and North Hertfordshire NHS Trust (Mount Vernon Cancer Centre)
Northwood, Middlesex, HA6 2RN, United Kingdom
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Virgen Macarena, University of Seville
Seville, Spain
-
IRCCS Istituto Clinico Humanitas
Rozzano, 20089, Italy
-
IRCSS Istituto Oncologico Veneto UOS Oncologia 2 del Melanoma Ospedale Busonera
Padova, 35128, Italy
-
IRCSS National Cancer Institute, "G.Pascale" Foundation Dip. CORP-S di Ricerca ed Assistenziale Cute, Melanoma lmmunologia Oncologica Sperimentale e Terapie Innovative
Naples, 80131, Italy
-
Institut Catala d'Oncologia - ICO L'Hospitalet
Barcelona, 08908, Spain
-
Royal Marsden Hospital
London, SW3 6JJ, United Kingdom
-
SSD Tumori Rari e Melanoma Viale Orazio Flacco
Bari, 70124, Italy
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Wirral, CH63 4JH, United Kingdom
-
University College London Hospital NHS
London, NW1 2PG, United Kingdom
-
University Hospital Southampton NHS Foundation
Southampton, SO16 6YD, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Supercharged immune cells take aim at childhood cancers
- Can a vaccine keep melanoma from coming back? large trial tests immune boosters
- Can a pill prevent eye cancer spread? new trial aims to find out
- New drug shows promise in shrinking eye cancer before surgery
- New drug combo aims to tackle Hard-to-Treat cancers
- 500 eye melanoma patients share their quality of life journey